Hydroxychloroquine Treatment for Prevention of Systemic Lupus Erythematosus

 描述：系统性红斑狼疮(SLE)是一种导致主要器官损害和寿命缩短的疾病。早期诊断和治疗是改善SLE患者预后的关键。然而，在早期阶段可靠识别系统性红斑狼疮的工具和基于证据的早期治疗方法是不可用的。我们建议，SLE的高危个体可以在早期或临床前阶段被识别，并具有足够的可靠性，以作为启动安全疗法治疗的目标人群，这种疗法有可能延迟或中止疾病的充分表现。这一人群有一些狼疮元素，但不完全符合分类标准，可称为不完全红斑狼疮(ILE)。目前的提案要求支持在ILE患者中进行一项多中心、安慰剂对照试验的计划阶段，以确定这种干预是否可以改善、推迟或防止进展为SLE。计划中的试验将对潜在的生物标记物进行密集采样，以阐明潜在的疾病和药物机制。在规划阶段，四个合作地点将敲定一项协议，准备所有必要的研究文件和手册，确保药物和安慰剂的来源，并获得监管部门的批准。此外，还将进行模拟招聘场景，以确认招生可行。这项计划拨款的结果将是一项UM1申请，以进行临床试验，该试验结合了所有开发的材料和 将为实施做好准备。长期目标是通过针对早期事件改变狼疮治疗的轨迹，这些事件可以被调节以防止损害和改善结果。

 DESCRIPTION: Systemic lupus erythematosus (SLE) is a disease that causes major organ damage and shortens lifespan. Early diagnosis and treatment are essential to improving outcomes for SLE patients. However, tools for the reliable identification of SLE in early stages and evidenced based approaches to early treatment are not available. We propose that individuals who are at high risk of SLE can be identified in early or preclinical stages with sufficient reliability to serve as a target population for initiating treatment with a safe therapythat has potential to delay or abort full expression of disease. This population has some elements of lupus but does not fully satisfy classification criteria, and may be referred to as incomplete lupu erythematosus (ILE). The present proposal requests support for the planning phase of a multicenter, placebo controlled trial of hydroxychloroquine in ILE patients to determine whether this intervention can ameliorate, delay or prevent progression to SLE. The planned trial will be carried out with intensive sampling for potential biomarkers to elucidate underlying disease and drug mechanisms. During the planning phase, the four cooperating sites will finalize a protocol, prepare all needed study documents and manuals, secure a source for the medication and placebo and obtain regulatory approvals. In addition, mock recruitment scenarios will be carried out to confirm that enrollment is feasible. The results of this planning grant will be a UM1 application to conduct the clinical trial that incorporates all of the developed materials and that will be ready for implementation. The long-term objectives are to change the trajectory of lupus management by targeting early events that can be modulated to prevent damage and improve outcomes.